Company / Working Capital
Biofrontera Inc. Working Capital History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$6.2M
FY2025
5-year range
$5.0M / $32.6M
FY2021-FY2025
Trend
-28.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $5M to $6M over the past 2 years.
Based on SEC 10-K filings.
$6M in FY2025 with a 3-year CAGR of -42.5%.
Improved from $5M to $6M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -42.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -42.5%, indicating a declining trend.
- In FY2025, working capital decreased 28.7% year-over-year.
- Peak working capital was recorded in FY2022.
- Lowest working capital in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.2M | -28.7% |
| FY2024 | $8.7M | +74.0% |
| FY2023 | $5.0M | -84.7% |
| FY2022 | $32.6M | +0.0% |
| FY2021 | $32.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026